Firms Making Progress Developing Antibiotics

Emerging from the mounds of data presented at several recent high-level programs on infectious diseases were updates from two publicly traded San Diego drug companies that have collectively raised nearly $400 million to develop narrow-spectrum antibiotics...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

• 52 weekly issues
• Subscriber-only digital content every business day, plus full access to SDBJ.com archives
• Book of Lists — the most comprehensive business resource in San Diego
• NEW: San Diego 500 — influential business leaders you need to know

Yours for only $129

First name:

Last name:

Email:

Address:

Zip:

CC Number:

Cvv:

Exp Month:

Exp Year: